Petmedix
PetMedix enters into antibody discovery collaboration with Zoetis
PetMedix™ is pleased to announce a collaboration with Zoetis to develop novel, fully species-specific companion animal monoclonal antibody therapeutics...
PetMedix raises $37M Series B
PetMedix™ announces today the completion of an oversubscribed $37M (£27M) Series B financing round that will be used to...
PetMedix monoclonal antibodies outperform benchmarks in canine study
Successful performance of first-ever fully canine antibodies in dog trial paves the way for next-generation technology to meet therapeutic...